Memantine as an Additive Therapy in Patients With Traumatic Brain Injury
Key facts
- Who runs it
- Mansoura University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2/3
- People taking part
- 80 people, planned
- Started
- 25 Mar 2025
- Planned end
- 30 Nov 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Memantine
- Mannitol
- Record updated
- 6 April 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Patients between 18 and 70 years of age
- Patients mild (GCS 13-15) to moderate (GCS 9-12) TBI were assessed for the study eligibility
Who cannot take part
- Comorbid illnesses, such as diabetes mellitus, ischemic heart disease, acute myocardial infarction within the past 48 hours
- Acute or chronic renal insufficiency
- Hepatic diseases
- Autoimmune diseases
- Malignancies
- Pregnancy
- Patients unable to tolerate enteral feeding
- More than 24 hours (h) since traumatic injury
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Memantine has shown promise in mitigating secondary brain injury in previous studies. One study demonstrated that early memantine administration in moderate TBI patients resulted in lower serum neuron-specific enolase levels and improved Glasgow Coma Scale scores. However, other trials investigating memantine's impact on long-term cognitive function in TBI patients have yielded mixed results. There is a need for well-controlled studies to determine the efficacy of memantine in improving neurological and cognitive outcomes in patients with TBI.
The 2 groups in the trial
- Memantine groupExisting treatment, for comparison
Mild to moderate TBI patients will receive memantine. It will be given either orally or through a nasogastric tube for 7 days, starting on the first day of admission to the hospital and then continued for 3 weeks. The memantine dose in the first 7 days is 30 mg twice daily, while during the remaining 3 weeks the dose is 10 mg twice daily
Treatment: Memantine
- Control groupOther group
Mild to moderate TBI patients will be managed by mannitol or hypertonic saline to reduce brain swelling and analgesic for headache such as; acetaminophen.
Treatment: Mannitol
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 6 April 2025